Search results
Showing 7861 to 7875 of 8904 results
October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.
Process manual for the endorsement of guidance and quality standard support resources (PMG29)
The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.
Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)
February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.
Process guide for adoption support resources for health technologies (PMG23)
This process and methods guide has been withdrawn.
Medical technologies evaluation programme methods guide (PMG33)
This medical technologies evaluation programme methods guide has been replaced by the NICE HealthTech programme manual.
This guide has been updated and replaced by practical steps to improving the quality of care and services using NICE guidance.
This interim methods and process guide for the proportionate approach to technology appraisals has been incorporated into NICE health technology evaluations: the manual.
Medical technologies evaluation programme process guide (PMG34)
This medical technologies evaluation programme process guide has been replaced by the NICE HealthTech programme manual.
February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [ID6352]
In development Reference number: GID-TA11377 Expected publication date: TBC
Diabetes: statins for primary prevention of CVD (T2DM and 10% risk) (IND182)
This guidance has been updated and replaced by NICE indicator 274.
Atrial fibrillation: pulse rhythm assessment in people at risk (IND168)
This indicator has been withdrawn following National Screening Committee recommendations and ongoing research.
Weight management: BMI calculation in preceding 5 years (IND167)
This indicator has been withdrawn following discussions with the National Screening Committee.
This guidance has been updated and replaced by NICE indicator 277.
This indicator has been updated and replaced by NICE indicator 287.